{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:45:04Z","timestamp":1780789504323,"version":"3.54.1"},"reference-count":49,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T00:00:00Z","timestamp":1423699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The dermatologic adverse events (AEs) of various molecularly targeted therapies are well\u2010described in adult cancer patients. Little has been reported on the incidence and clinical presentation of such AEs in pediatric patients with cancer. To address this gap, we analyzed the dermatologic AEs reported across clinical trials of targeted anticancer therapies in pediatric patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedures<\/jats:title><jats:p>We conducted an electronic literature search (PubMed, American Society of Clinical Oncology annual meetings' abstracts, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>, NCI's Pediatric Oncology Branch webpage) to identify clinical trials involving targeted anticancer therapies that reported dermatologic AEs in their safety data. Studies were limited to the pediatric population, monotherapy trials (oncology), and English language publications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Pooled data from 19 clinical studies investigating 11 targeted anticancer agents (alemtuzumab, rituximab, imatinib, dasatinib, erlotinib, vandetanib, sorafenib, cabozantinib, pazopanib, everolimus, and temsirolimus) were analyzed. The most frequently encountered dermatologic AEs were rash (127\/660; 19%), xerosis (18\/100; 18%), mucositis (68\/402; 17%), and pruritus (12\/169; 7%). Other AEs included pigmentary abnormalities of the skin\/hair (13%), hair disorders (trichomegaly, hypertrichosis, alopecia, and madarosis; 14%), urticaria (7%), palmoplantar erythrodysesthesia (7%), erythema, acne, purpura, skin fissures, other \u2018unknown skin changes\u2019, exanthem, infection, flushing, telangiectasia, and photosensitivity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study describes the dermatologic manifestations of targeted anticancer therapy\u2010related AEs in the pediatric population. Since these AEs are often associated with significant morbidity, it is imperative that pediatric oncologists be familiar with their recognition and management, to avoid unnecessary dose modifications and\/or termination, and to prevent impairments in patients' quality of life. Pediatr Blood Cancer 2015;62:798\u2013806. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.25429","type":"journal-article","created":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T12:14:23Z","timestamp":1423829663000},"page":"798-806","source":"Crossref","is-referenced-by-count":28,"title":["Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis"],"prefix":"10.1002","volume":"62","author":[{"given":"Viswanath Reddy","family":"Belum","sequence":"first","affiliation":[{"name":"Department of Dermatology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Washington","sequence":"additional","affiliation":[{"name":"Department of Dermatology Memorial Sloan Kettering Cancer Center New York New York"},{"name":"Philadelphia College of Osteopathic Medicine Suwanee Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A.","family":"Pratilas","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Memorial Sloan Kettering Cancer Center New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[{"name":"Department of Dermatology Institut Claudius Regaud Institut Universitaire Cancer Toulouse\u2010oncopole Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Boralevi","sequence":"additional","affiliation":[{"name":"Unit \u00e9  de Dermatologie P\u00e9diatrique H\u00f4pital Pellegrin\u2010enfants Place Am\u00e9lie Raba\u2010L\u00e9on Bordeaux Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[{"name":"Department of Dermatology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70530-2"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.3611"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2012.01.009"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25090"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0021-0"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1301930"},{"key":"e_1_2_6_8_1","unstructured":"National Cancer Institute\u2010Center for Cancer Research. Clinical Trials. Pediatric Oncology Branch home page.http:\/\/citfms1.cit.nih.gov\/pob\/clinical_trials\/index1.phpLast reviewed May 22 2014 Accessed June 10 2014.2014."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2012.09.012"},{"key":"e_1_2_6_10_1","unstructured":"BoyettJM.2014. Imatinib mesylate with or without radiation therapy in treating young patients with newly diagnosed or recurrent glioma. In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010\u2010 [cited Jul 14]. Available from:https:\/\/clinicaltrials. gov\/show\/NCT 00021229 NLM Identifier: NCT00021229 NLM Identifier: NCT00021229."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.7231"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.8280"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq141"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0071"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3284"},{"key":"e_1_2_6_16_1","first-page":"10078","article-title":"A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children's Oncology Group phase I consortium trial","volume":"32","author":"Chuk MK","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.0914"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182815428"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.4649"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22209"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.6791"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.05.008"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21132"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.09.021"},{"key":"e_1_2_6_25_1","unstructured":"Astellas Pharma Inc. Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma (PETEY) In: ClinicalTrials. gov [Internet] Bethesda (MD): National Library of Medicine (US) 2013\u2010 [cited 2014 Jul 14]. Available from:https:\/\/clinicaltrials.gov\/show\/NCT01032070NLM Identifier: NC T010320702013."},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61134-9"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.03.007"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.694076"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.9230"},{"key":"e_1_2_6_30_1","first-page":"1462","article-title":"Dermatologic challenges in cancer patients and survivors","volume":"21","author":"Agha R","year":"2007","journal-title":"Oncol (Williston Park)"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12874601"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-04-0238"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2006.s.008"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055128"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1360"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12052"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1159\/000078818"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.09.023"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(99)00138-1"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1013027"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2011.03.028"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24696"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1362"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.7356"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2012.11.008"},{"key":"e_1_2_6_46_1","first-page":"1959","article-title":"Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development","volume":"150","author":"Hansen LA","year":"1997","journal-title":"Am J Pathol"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.11.028"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0271fje"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn389"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1404-0"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25429","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.25429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T18:56:49Z","timestamp":1696532209000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.25429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,12]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1002\/pbc.25429"],"URL":"https:\/\/doi.org\/10.1002\/pbc.25429","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,12]]}}}